05/07/2026 Download(opens in new window) Increased 2026 revenue guidance from $510 million to $525 million Achieved record-high quarterly revenues, Adjusted EBITDA__1 and Adjusted EBITDA per share__1 since inception MONTREAL, May 07, 2026 (GLOBE…
05/07/2026
Download(opens in new window)
Increased 2026 revenue guidance from $510 million to $525 million
Achieved record-high quarterly revenues, Adjusted EBITDA__1 and Adjusted EBITDA per share__1 since inception
MONTREAL, May 07, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) pharmaceutical company, today reported financial results for its first quarter ended March 31, 2026. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.
Q1-26 Highlights
Financial Results - IFRS
-
Revenues were $148,439, an increase of $60,363 or 69% over the same period in prior year. The increase was primarily driven by the incremental revenues from the Paladin and Sumitomo portfolios, the growth of our promoted products, and the purchasing patterns of certain products including Ambisome® deliveries to the MOH.
-
Gross margin was $69,109 or 47% of revenues compared to $34,866 or 40% of revenues in the same period in prior year. The increase in gross margin % was driven by both a higher contribution of the Canadian business in Q1-26 compared to Q1-25 and the lower impact of hyperinflation2, partly offset by product mix including a higher proportion of Ambisome® deliveries to the MOH.
-
Operating income was $10,578 compared to an operating loss of $5,537 in the same period in prior year.
-
Net income was $13,169, compared to $2,185 in the same period in prior year.
-
Net income per share was $0.13, compared to $0.02 in the same period in prior year.
-
Generated cash inflow from operations of $40,694, and ended Q1-26 with over $125,000 in cash, cash equivalents and marketable securities.
Financial Results - Non-GAAP
-
Adjusted Revenues1 were $147,594, an increase of $59,615 or 68% over the same period in prior year, or $55,395 or 60% on a constant currency1 basis, primarily driven by the incremental revenues from the Paladin and Sumitomo portfolios, the growth of our promoted products, and the purchasing patterns of certain products including Ambisome® deliveries to the MOH.
-
Adjusted Gross Margin1 was $70,648 or 48% of Adjusted Revenues1 compared to $40,934 or 47% of Adjusted Revenues1 in the same period in prior year.. The increase in the Adjusted Gross Margin1 % was driven by a higher contribution of the Canadian business in Q1-26 compared to Q1-25, partly offset by product mix including a higher proportion of Ambisome® deliveries to the MOH.
-
Adjusted EBITDA1 was $27,917, an increase of $15,804 or 130% over the same period in prior year.
-
Adjusted EBITDA per share1 was $0.28, an increase of $0.16 or 133% over the same period in prior year.
Trailing Twelve Months Financial Results - Non-GAAP
- Adjusted Revenues1 for the trailing twelve months ending March 31, 2026 were $511,966, an increase of $144,370 or 39% over the same period in prior year.
Corporate developments
-
Executed an asset purchase agreement to acquire a manufacturing facility in Argentina.
-
Amended previously announced NCIB to purchase up to 6,190,493 common shares of the Company up to August 21, 2026. In Q1-26, the Company purchased 1,323,200 common shares at an average price of $6.22 for aggregate cash consideration of $8,233.
-
Repaid principal of $10,000 on the revolving credit facility, and ended Q1-26 with over $58,000 in bank loans.
Products
-
Executed certain agreements with two partners to return the Canadian commercial rights of six non‑core products in exchange for $21,500 (the "Settlement Agreements") and, in accordance with the Asset Purchase Agreement, paid Paladin $8,442 in April 2026 for the final settlement of the holdback.
-
Submitted multiple products for regulatory approval across our territories:
-
Niktimvo® (axatilimab) in Brazil.
-
Supplemental indication of Minjuvi® (tafasitamab) for follicular lymphoma (FL) in Argentina and Mexico.
-
Obtained regulatory approval and launched the following products:
-
Supplemental indication of Minjuvi® (tafasitamab) for FL in Brazil.
-
Bapocil® (palbociclib) in Colombia.
S****ubsequent to quarter-end
-
Launched Pemazyre® (pemigatinib) in Argentina.
-
Launched Akynzeo® (netupitant/palonosetron/fosnetupitant/palonosetron) in Paraguay.
-
Withdrew the Health Canada New Drug Submission for Qelbree® due to certain manufacturing changes by our partner. The Company expects to resubmit Qelbree® for approval at a later date.
-
Purchased 119,200 common shares through Knight's NCIB at an average purchase price of $7.45 for an aggregate cash consideration of $888.
-
Repaid $10,000 of principal of the Credit Facility, and reduced the outstanding principal balance to $20,000.
-
Shareholders re-elected Jonathan Ross Goodman, Samira Sakhia, James C. Gale, Robert N. Lande, Michael J. Tremblay, Nicolás Sujoy, and Janice Murray on the Board of Directors.
“I am pleased to announce that we continue to deliver record results and cash flows from our operations. For the quarter ended March 31, 2026, revenues were over $148 million, an increase of $60 million or 68%, and Adjusted EBITDA1 was $28 million, an increase of $16 million or 130%. Over the last 12 months we have generated over $500 million in revenues, which reflects the contributions from the growth of our promoted products, including over fifteen launches over the last two years, as well as the incremental revenues from the mature cash flow generating products we acquired last year,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc. “In addition, we are increasing our forecast for fiscal 2026 and expect to deliver over $500 million in revenues, which is double the size of our business from five years ago.”
____________________________________
1 Adjusted Revenues, revenues at constant currency_,_ Adjusted Gross Margin_, Adjusted EBITDA and A__djusted EBIT__DA per share_ are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section - Financial Results under Non-GAAP measures for additional details.
2 Refers to the impact of hyperinflation due to the application of IAS 29 in Argentina. Refer to section - Hyperinflation for additional details.
| | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SELECT FINANCIAL RESULTS REPORTED UNDER IFRS [In thousands of Canadian dollars] | | | | | | | | |
| | | | | | | | | |
| | | | | | Change | | | |
| | Q1-26 | | Q1-25 | | $1 | | %2 | |
| | | | | | | | | |
| Revenues | 148,439 | | 88,076 | | 60,363 | | 69% | |
| Gross margin | 69,109 | | 34,866 | | 34,243 | | 98% | |
| Gross margin % | 47****% | | 40_%_ | | | | | |
| Selling and marketing | 20,321 | | 13,924 | | (6,397 | ) | 46% | |
| General and administrative | 14,127 | | 12,219 | | (1,908 | ) | 16% | |
| Research and development | 9,410 | | 4,786 | | (4,624 | ) | 97% | |
| Amortization of intangible assets | 14,673 | | 9,474 | | (5,199 | ) | 55% | |
| Operating expenses | 58,531 | | 40,403 | | (18,128 | ) | 45% | |
| | | | | | | | | |
| Operating income (loss) | 10,578 | | (5,537 | ) | 16,115 | | N/A | |
| | | | | | | | | |
| Net income for the period | 13,169 | | 2,185 | | 10,984 | | 503% | |
_1 A positive variance represents a positive impact to net income and a negative variance represents a negative impact to net income.
__2 Percentage change is presented in absolute values.
_
Revenues: For the quarter ended March 31, 2026, revenues increased by $60,363 or 69% compared to the same period in prior year. Excluding IAS 291, the increase was $59,615 or 68% and $55,395 or 60% on a constant currency2 basis. The mature products of the Paladin and Sumitomo portfolios contributed $17,037 of incremental revenues. The remainder of the increase was due to the growth of our promoted products and the purchasing patterns of certain products including Ambisome® deliveries to the MOH which were $14,115 higher in Q1-26 compared to Q1-25. Excluding the sales of Ambisome® to the MOH, our promoted portfolio grew by $27,192 or 60%.
The Company categorizes its revenues by product portfolio, as defined as follows:
Promoted - Launched Pipeline Products: Promoted products currently in the early stage of launch, typically having been introduced to the market within the past five years.
Promoted - Strategic Products: Promoted products that have reached, or are approaching, their peak potential, typically having been introduced to the market over five years ago.
Mature: Products that require lower levels of promotional activity and/or have reached their peak potential.
Discontinued: Products that the Company has stopped commercializing or is in the process of discontinuing.
Our revenues by product portfolio are as follows:
| | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | | | Change | | | |
| Product Portfolio | Q1-26 | | Q1-251 | | $ | | % | |
| Promoted | | | | | | | | |
| Promoted - Launched Pipeline Products | 15,336 | | 2,466 | | 12,870 | | 522% | |
| Promoted - Strategic Products | 83,916 | | 55,269 | | 28,647 | | 52% | |
| Total Promoted | 99,252 | | 57,735 | | 41,517 | | 72% | |
| Mature | 47,026 | | 29,819 | | 17,207 | | 58% | |
| Discontinued | 2,161 | | 522 | | 1,639 | | 314% | |
| Total Revenues | 148,439 | | 88,076 | | 60,363 | | 69% | |
1 Comparative figures have been reclassified to align with the three-month period ended March 31, 2026 reporting presentation. These reclassifications had no impact on total revenues.
-
Promoted Portfolio: For the quarter ended March 31, 2026, the Promoted Portfolio increased by $41,517 or 72%. Excluding IAS 291, the Promoted Portfolio increased by $41,307 or 72%.
-
The Launched Pipeline Products grew by $12,863 or 522%. Since January 2024, Knight has launched multiple products in multiple countries, including Minjuvi® for DLBCL in Brazil, Mexico and Argentina, Minjuvi® for FL in Brazil, Pemazyre® in Brazil and Mexico, Bapocil® in Colombia, and Imvexxy®, Bijuva®, Jornay PM®, Xcopri®, Myfembree® and Orgovyx® in Canada.
-
The Strategic Products increased by $28,444 or 51% driven by growth of the portfolio, as well as purchasing patterns including the MOH purchases of Ambisome® which were $14,115 higher in Q1-26 compared to Q1-25. Excluding the MOH purchases of Ambisome®, the Strategic Products grew by $14,329 or 34%.
-
Mature Portfolio: For the quarter ended March 31, 2026, the increase in the Mature portfolio was driven by incremental revenues from the Paladin and Sumitomo portfolios.
-
Discontinued: For the quarter ended March 31, 2026, the Discontinued portfolio revenues increased $1,639 or 314%. The increase is due to certain agreements executed with two partners to return the Canadian commercial rights of six non core products in exchange for $21,500.
Gross margin: For the quarter ended March 31, 2026, gross margin was $69,109 or 47% compared to $34,866 or 40% in Q1-25. Excluding the Hyperinflation Impact1, the Adjusted Gross Margin2 was $70,648 in Q1-26, an increase of $29,714 compared to Q1-25, due to the growth of revenues. The Adjusted Gross Margin2 as a % of Adjusted Revenues2, was 48% in Q1-26 compared to 47% in Q1-25. The increase was driven by the higher contribution of the Canadian business in Q1-26 compared to Q1-25, which generates a higher Adjusted Gross Margin2 as a % of Adjusted Revenues2, partly offset by product mix including a higher proportion of Ambisome® deliveries to the MOH.
Selling and marketing (“S&M”) expenses: For the quarter ended March 31, 2026, S&M expenses increased by $6,397 or 46%. The increase was mainly driven by an expansion in our sales and commercial structure to support the Paladin portfolio, the recent launches in the Sumitomo portfolio and Jornay PM®, as well as the launch of Minjuvi® in Mexico. In addition to structure, the increase also included our promotion and marketing expenses for the brands acquired in the Paladin and Sumitomo portfolios including Orgovyx®, Myfembree®, Xcopri® and Envarsus®PA, as well as for the recently launched brands including Jornay PM® in Canada, Minjuvi® in Mexico and Argentina, Pemazyre® in Mexico and Brazil, and pre-launch activities including Tavalisse® in Mexico and Brazil.
General and administrative (“G&A”) expenses: For the quarter ended March 31, 2026, G&A expenses increased by $1,908 or 16%. The increase was mainly due to an increase in our structure due to the addition of the Paladin and Sumitomo portfolios and higher spending on professional and consulting fees.
Research and development (“R&D”) expenses: For the quarter ended March 31, 2026, R&D expenses increased by $4,624 or 97%. The increase was mainly due to the expansion of our scientific affairs structure including field‑based medical personnel related to the Paladin and Sumitomo portfolios. In addition to structure, the increase included incremental medical, regulatory, and pharmacovigilance spend on the Paladin and Sumitomo portfolios, as well as development, regulatory, pre‑launch, and launch expenses on our pipeline and new launches, including Niktimvo®, Minjuvi®, Jornay PM®, Pemazyre®, Crexont® and Tavalisse®.
Net Income
For the quarter ended March 31, 2026, the net income was $13,169 compared to $2,185 for the same period in prior year. The variance was mainly driven by the above-mentioned items, as well as changes in amortization of intangible assets, net loss on financial assets measured at fair value through profit or loss, foreign exchange gain, gain on hyperinflation, interest income or expense, and income tax expense.
____________________________________
_1 Refers to the impact of hyperinflation due to the application of IAS 29 in Argentina. Refer to section - Hyperinflation for additional details.
_2 Adjusted Revenues, revenues at constant currency and Adjusted Gross Margin are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section - Financial Results under Non-GAAP measures for additional details.
| | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SELECT BALANCE SHEET ITEMS [In thousands of Canadian dollars] | | | | | | | | |
| | | | | | | | | |
| | | | | | Change | | | |
| As at | March 31, 2026 | | December 31, 2025 | | **$**1 | | **%**2 | |
| | | | | | | | | |
| Cash, cash equivalents and marketable securities | 127,290 | | 95,283 | | 32,007 | | 34% | |
| Trade and other receivables | 196,343 | | 178,598 | | 17,745 | | 10% | |
| Inventories | 141,918 | | 135,866 | | 6,052 | | 4% | |
| Financial assets | 94,717 | | 98,430 | | (3,713 | ) | 4% | |
| Intangible assets | 354,037 | | 379,510 | | (25,473 | ) | 7% | |
| Accounts payable and accrued liabilities | 153,114 | | 125,755 | | 27,359 | | 22% | |
| Bank loans | 58,639 | | 67,895 | | (9,256 | ) | 14% | |
_1 A positive variance represents a positive impact to net assets and a negative variance represents a negative impact to net assets.
__2 Percentage change is presented in absolute values.
_
Cash, cash equivalents and marketable securities: As at March 31, 2026, Knight had $127,290 in cash, cash equivalents and marketable securities, an increase of $32,007 or 34%, compared to December 31, 2025. The increase is mainly driven by operating cash inflows of $40,694 and proceeds of $17,000 from the return of the Canadian commercial rights for certain non-core products. These increases were partly offset by principal repayments of bank loans of $11,329, the repurchase of common shares under the NCIB of $8,237, investment in intangible assets of $4,152, and the acquisition of a manufacturing facility in Argentina of $2,950.
Trade and other receivables: As at March 31, 2026, trade and other receivables were $196,343, an increase of $17,745 or 10%, compared to December 31, 2025, due to the growth across our portfolio including the timing of deliveries of Ambisome® to the MOH, as well as the receivable of $4,500 remaining under the Settlement Agreements. The amount is expected to be collected in H2-26.
Inventories: As at March 31, 2026, inventories were $141,918, an increase of $6,052 or 4%, compared to December 31, 2025, primarily due to the timing of purchases and foreign exchange revaluation, partly offset by sales during the period.
Financial assets: As at March 31, 2026, financial assets were $94,717, a decrease of $3,713 or 4%, compared to December 31, 2025. This decrease was driven by a decrease in equity investments of $3,055 mainly due to the revaluation of our publicly traded equity investments and the disposal of certain equities during the period, as well as a decrease in fund investments of $658, which included a decrease in fair value of $350 and a return of capital of $308.
Intangible assets: As at March 31, 2026, intangible assets were $354,037, a decrease of $25,473 or 7%, compared to December 31, 2025, primarily due to the derecognition of intangible assets in connection with the Settlement Agreements, as well as amortization, partly offset by the appreciation of USD vs CAD.